Magazine

Magazine

August 2017, Volume 3, Issue 10

This issue features a comparison between American and European drug approval processes, a conversation with a lymphoma doctor running for Congress, highlights from recent hematology/oncology meetings, and more.

July Bonus Mid-Year Edition

This bonus issue features conversations with families joined by hematology, highlights from recent hematology/oncology meetings, and more.

July 2017, Volume 3, Issue 8

This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.

June 2017, Volume 3, Issue 7

This issue features a look at NIH's new data-sharing requirements, Mikkael Sekeres' thoughts on contract research organizations, and more.

May 2017 Special Edition

This special edition features updates in the world of myeloid malignancies, including a review of investigational treatment options and news from recent hematologic conferences.

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.

April 2017, Volume 3, Issue 5

This issue examines the art and science of myeloma drug sequencing, Mikkael Sekeres' letter to the ABIM, highlights from the 16th International Myeloma Workshop, and more.

March 2017, Volume 3, Issue 4

This issue takes a look at diversity in the medical education system, provides a hematology drug pipeline update, and more.

February 2017, Volume 3, Issue 3

This issue features highlights from the 2016 ASH Annual Meeting, a look at the dangers of predatory publishing, and more.

January 2017 Annual Meeting Edition

This issue features expanded coverage of the 2016 ASH Annual Meeting, as well as a focus on CAR T-cell therapy, and more.
Advertisement

Current Issue

August 2017, Volume 3, Issue 10

This issue features a comparison between American and European drug approval processes, a conversation with a lymphoma doctor running for Congress, highlights from recent hematology/oncology meetings, and more.